Supreme Court Quashes Rajasthan Village Renaming, Says Government Must Follow its Own Policy  ||  NCLAT: NCLT Can Order Forensic Audit on its Own, No Separate Application Required  ||  NCLAT Reiterates That IBC Cannot be Invoked as a Recovery Tool for Contractual Disputes  ||  Delhi HC: DRI or Central Revenues Control Lab Presence in Delhi Alone Does Not Confer Jurisdiction  ||  Delhi High Court: Software Receipts Not Taxable on PE Basis Already Rejected by ITAT  ||  Delhi High Court: Statutory Appeals Cannot Be Denied Due to DRAT Vacancies or Administrative Delays  ||  J&K&L HC: Failure to Frame Limitation Issue Not Fatal; Courts May Examine Limitation Suo Motu  ||  Bombay HC: Preventing Feeding Stray Dogs at Society or Bus Stop is Not 'Wrongful Restraint'  ||  Gujarat HC: Not All Injuries Reduce Earning Capacity; Functional Disability Must Be Assessed  ||  Delhi HC: Framing of Charges is Interlocutory and Not Appealable under Section 21 of NIA Act    

Finalization of Draft Rules on Sale of Drugs by E-Pharmacies- (Press Information Bureau) (25 Jun 2019)

MANU/PIBU/0667/2019

Law of Medicine

The Government has published draft rules vide G.S.R. 817 (E) dated 28th August 2018 for inviting public/stakeholder comments for amendment to the Drugs and Cosmetics Rules, 1945 for incorporating provisions relating to regulation of sale and distribution of drugs through e-pharmacy. A large number of suggestions/comments have been received from the stakeholders, which are being examined. At the same time, the matter is sub-judice before various Hon'ble High Courts in the country. Therefore, no timeline for finalization of the rules can be provided.

Under the Drugs & Cosmetics Act and Rules, sale of spurious drugs is a punishable offence and State Licensing Authorities are empowered to take action in this regard. Accordingly, the complaints as received, are referred to State Licensing Authorities for taking action as per the provisions of the Act and Rules.

Tags : DRAFT RULES   FINALIZATION   SALE OF DRUGS   E-PHARMACIES  

Share :        

Disclaimer | Copyright 2025 - All Rights Reserved